ALK and non-small cell lung carcinoma: Utilizing medicinal chemistry and rational design, different groups have then been successful in the synthesis of novel, selective and potent ALK inhibitors with acceptable and consistent pharmacokinetic and pharmacodynamics profiles displaying strong in vivo efficacy in ALK-positive NSCLC xenograft models at well-tolerated doses.